Safety and efficacy of biosimilars in oncology

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages e502-e509

  Schellekens, Huub ^a   Smolen, Josef S ^b   Dicato, Mario ^c   Rifkin, Robert M ^d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^d The US Oncology Network McKesson Specialty Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; CT P13; ETANERCEPT; FILGRASTIM; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SB2; MYL 14010; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; CT-P13;

ANKYLOSING SPONDYLITIS; ANTIGEN BINDING; BATCH PROCESS; BINDING AFFINITY; BREAST CANCER; CANCER THERAPY; CLINICAL EFFECTIVENESS; CROHN DISEASE; DRUG APPROVAL; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; HUMAN; IMMUNOGENICITY; PATIENT CARE; PHYSICAL CHEMISTRY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; ULCERATIVE COLITIS; NEOPLASMS;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; HUMANS; NEOPLASMS;

EID: 84995704268     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30374-6     Document Type: Review

References (66)

1. 1 Weise, M, Bielsky, MC, De Smet, K, et al. Biosimilars-why terminology matters. Nat Biotechnol 29 (2011), 690–693.
2. 2 Baeshen, MN, Al-Hejin, AM, Bora, RS, et al. Production of biopharmaceuticals in E. coli: current scenario and future perspectives. J Microbiol Biotechnol 25 (2015), 953–962.
3. 3 Read, EK, Park, JT, Brorson, KA, Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnol Appl Biochem 58 (2011), 213–219.
4. 4 Schiestl, M, Stangler, T, Torella, C, Cepeljnik, T, Toll, H, Grau, R, Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29 (2011), 310–312.
5. 5 Schellekens, H, Ryff, JC, ‘Biogenerics’: the off-patent biotech products. Trends Pharmacol Sci 23 (2002), 119–121.
6. 6 European Medicines Agency. EMA Guideline on similar biological medicinal products, CHMP/437/04. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf, Oct 30, 2005 (accessed Sept 29, 2016).
7. 7 Kurki, P, Ekman, N, Biosimilar regulation in the EU. Expert Rev Clin Pharmacol 8 (2015), 649–659.
8. 8 Casadevall, N, Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 18:suppl 8 (2003), 37–41.
9. 9 Lee, JF, Litten, JB, Grampp, G, Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28 (2012), 1053–1058.
10. 10 Mellstedt, H, Anti-neoplastic biosimilar—the same rules as for cytotoxic generics cannot be applied. Ann Oncol 24:suppl 5 (2013), 23–28.
11. 11 Ebbers, HC, van Meer, PJ, Moors, EH, Mantel-Teeuwisse, AK, Leufkens, HG, Schellekens, H, Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 18 (2013), 872–879.
12. 12 Joung, J, Robertson, JS, Griffiths, E, Knezevic, I, WHO Informal Consultation Group. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19–20 April 2007. Biologicals 36 (2008), 269–276.
13. 13 Generics and Biosimilars Initiative. About GaBI. http://gabionline.net/About-GaBI, 2015 (accessed May 11, 2016).
14. 14 McCamish, M, Woollett, G, The state of the art in the development of biosimilars. Clin Pharmacol Ther 91 (2012), 405–417.
15. 15 McCamish, M, Woollett, G, Worldwide experience with biosimilar development. MAbs 3 (2011), 209–217.
16. 16 European Medicines Agency. EMA guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf, 2006 (accessed May 23, 2016).
17. 17 US Department of Health and Human Services. Guidance for industry scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf, 2015 (accessed May 23, 2016).
18. 18 Schneider, CK, Vleminckx, C, Gravanis, I, et al. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 30 (2012), 1179–1185.
19. 19 European Medicines Agency. European Public Assessment Reports—biosimilars. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit (accessed July 8, 2016).
20. 20 Li, E, Subramanian, J, Anderson, S, Thomas, D, McKinley, J, Jacobs, IA, Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther 9 (2015), 3247–3255.
21. 21 Vogel, CL, Cobleigh, MA, Tripathy, D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002), 719–726.
22. 22 Colombat, P, Salles, G, Brousse, N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001), 101–106.
23. 23 Witzig, TE, Vukov, AM, Habermann, TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005), 1103–1108.
24. 24 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf, 2015 (accessed May 11, 2016).
25. 25 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Concept paper on the revision of the guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant granulocyte-colony stimulating factor. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/07/WC500190635.pdf, 2005 (accessed May 11, 2016).
26. 26 Kooijman, M, van Meer, PJ, Moors, EH, Schellekens, H, Thirty years of preclinical safety evaluation of biopharmaceuticals: did scientific progress lead to appropriate regulatory guidance?. Expert Opin Drug Saf 11 (2012), 797–801.
27. 27 Ebbers, HC, Al-Temimi, E, Moors, EH, Mantel-Teeuwisse, AK, Schellekens, H, Leufkens, HG, Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules. BioDrugs 27 (2013), 167–174.
28. 28 Afzali, A, Wheat, CL, Hu, JK, Olerud, JE, Lee, SD, The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis 8 (2014), 480–488.
29. 29 Liu, PM, Zou, L, Sadhu, C, Shen, WD, Nock, S, Comparative immunogenicity assessment: a critical consideration for biosimilar development. Bioanalysis 7 (2015), 373–381.
30. 30 Ben-Horin, S, Heap, GA, Ahmad, T, Kim, H, Kwon, T, Chowers, Y, The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?. Expert Rev Gastroenterol Hepatol 9:suppl 1 (2015), 27–34.
31. 31 Ben-Horin, S, Yavzori, M, Benhar, I, et al. Cross-immunogenicity: antibodies to infliximab in remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 65 (2016), 1132–1138.
32. 32 Krieckaert, CL, Jamnitski, A, Nurmohamed, MT, Kostense, PJ, Boers, M, Wolbink, G, Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 64 (2012), 3850–3855.
33. 33 Murdaca, G, Spanò, F, Contatore, M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. Expert Opin Drug Saf 15 (2016), 43–52.
34. 34 The INN crowd. Nat Biotechnol, 31, 2013, 1055.
35. 35 Minghetti, P, Rocco, P, Schellekens, H, The constrained prescription, interchangeability and substitution of biosimilars. Nat Biotechnol 33 (2015), 688–689.
36. 36 Dowlat, HA, Kuhlmann, MK, Khatami, H, Ampudia-Blasco, FJ, Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications. Diabetes Obes Metab 18 (2016), 737–746.
37. 37 Generics and Biosimilars Initiative. EU guidelines for biosimilars. http://gabionline.net/Guidelines/EU-guidelines-for-biosimilars, 2010 (accessed May 11, 2016).
38. 38 Ebbers, HC, Muenzberg, M, Schellekens, H, The safety of switching between therapeutic proteins. Expert Opin Biol Ther 12 (2012), 1473–1485.
39. 39 Schellekens, H, Lietzan, E, Faccin, F, Venema, J, Biosimilar monoclonal antibodies: the scientific basis for extrapolation. Expert Opin Biol Ther 15 (2015), 1633–1646.
40. 40 Kurki, P, Bielsky, MC, ECCO position challenged by European drug regulators. J Crohns Colitis, 8, 2014, 258.
41. 41 European Medicines Agency. Summary of opinion (infliximab biosimilar). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002576/WC500144832.pdf, 2013 (accessed May 11, 2016).
42. 42 Yoo, DH, Hrycaj, P, Miranda, P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72 (2013), 1613–1620.
43. 43 Park, W, Hrycaj, P, Jeka, S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72 (2013), 1605–1612.
44. 44 Mack, A, Norway, biosimilars in different funding systems. What works?. GaBI J 4 (2015), 90–92.
45. 45 FirstWord. ViewPoints: Denmark joins Norway in securing a 60 percent-plus discount for biosimilar remicade—what impact on the rest of Europe?. http://www.fwbiosimilars.com/viewpoints-denmark-joins-norway-securing-60-percent-plus-discount-biosimilar-remicade-%E2%80%93-what-impact (accessed July 8, 2016).
46. 46 Tracey, D, Klareskog, L, Sasso, EH, Salfeld, JG, Tak, PP, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117 (2008), 244–279.
47. 47 Blandizzi, C, Gionchetti, P, Armuzzi, A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 27:suppl 1 (2014), 1–10.
48. 48 King, S, FirstWord Lists—the best selling drugs in 2014. http://www.firstwordpharma.com/node/1263906#axzz3lWvxPzF4, 2015 (accessed July 8, 2016).
49. 49 Moćko, P, Kawalec, P, Pilc, A, Safety profile of biologic drugs in the treatment of inflammatory bowel diseases: a systematic review and network meta-analysis of randomized controlled trials. Clin Drug Investig, 2016, 10.1007/s40261-016-0459-y published online Sept 7.
50. 50 Jung, SK, Lee, KH, Jeon, JW, et al. Physicochemical characterization of remsima. MAbs 6 (2014), 1163–1177.
51. 51 Yoo, DH, Prodanovic, N, Jaworski, J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208786 published online April 29.
52. 52 Park, W, Yoo, DH, Miranda, P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis, 2016, 10.1136/annrheumdis-2015-208783 published online April 26.
53. 53 Choe, JY, Prodanovic, N, Niebrzydowski, J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2015-207764 published online Aug 28.
54. 54 Emery, P, Vencovský, J, Sylwestrzak, A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis, 2015, 10.1136/annrheumdis-2015-207588 published online July 6.
55. 55 Danese, S, Gomollon, F, ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 7 (2013), 586–589.
56. 56 Tebbey, PW, Varga, A, Naill, M, Clewell, J, Venema, J, Consistency of quality attributes for the glycosylated monoclonal antibody Humira(R) (adalimumab). MAbs 7 (2015), 805–811.
57. 57 Rugo, HS, Barve, A, Waller, CF, et al. HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. Proc Am Soc Clin Oncol, 34(suppl), 2016 abstr LBA503.
58. 58 Yin, D, Barker, KB, Li, R, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol 78 (2014), 1281–1290.
59. 59 Wisman, LA, De Cock, EP, Reijers, JA, et al. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin Drug Investig 34 (2014), 887–894.
60. 60 Hanes, V, Born, T, Chow, V, et al. Comparative similarity of ABP 980 and trastuzumab: results of functional similarity and human pharmacokinetic assessment. Cancer Res, 76(suppl 4), 2016 P6-13-12 (abstr).
61. 61 Morita, J, Tanaka, M, Nomoto, M, et al. Pharmacokinetic bioequivalence, safety, and immunogenicity of DMB-3111, a trastuzumab biosimilar, and trastuzumab in healthy Japanese adult males: results of a randomized trial. BioDrugs 30 (2016), 17–25.
62. 62 Pivot, X, Curtit, E, Lee, YJ, et al. A randomized phase i pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther 38 (2016), 1665–1673.
63. 63 Gascon, P, The evolving role of biosimilars in haematology-oncology: a practical perspective. Ther Adv Hematol 6 (2015), 267–281.
64. 64 FDA. CT-P13 (infliximab biosimilar) briefing document for the Arthritis Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484860.pdf, 2016 (accessed May 20, 2016).
65. 65 Davis, J, Biosimilar cost savings in Europe beyond 25% might cull sponsors, EGA warned, 2015, The Pink Sheet Daily, London.
66. 66 ICH Harmonized Tripartite Guideline. Comparability of biotechnological/biological products subject to changes in their manufacturing process—Q5E. http://www.ich.org/products/guidelines/quality/quality-single/article/comparability-of-biotechnologicalbiological-products-subject-to-changes-in-their-manufacturing-proc.html, 2004 (accessed Sept 29, 2016).